Form 4: Edwards Lifesciences Executive Jean-Luc Lemercier Reports Stock and Option Grants

Jean-Luc Lemercier, CVP of EMEACLA and JAPAC at Edwards Lifesciences, reports the acquisition of stock and option awards.

Summary

• On May 7, 2024, Jean-Luc Lemercier, CVP of EMEACLA and JAPAC at Edwards Lifesciences, reported changes in beneficial ownership.
• Lemercier acquired 7,125 shares of common stock and disposed of 46 shares at $85.09.
• Following these transactions, Lemercier directly owns 184,788.8055 shares of common stock.
• Lemercier also acquired options to purchase 42,200 shares of common stock at an exercise price of $85.84, which become exercisable starting June 7, 2024, in monthly installments, expiring on May 6, 2031.
• Additionally, Lemercier was granted 7,125 performance rights, which will vest on May 7, 2027, based on the achievement of certain performance goals.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The filing reflects standard executive compensation practices, aligning management interests with shareholders through equity-based incentives. There are no overtly negative implications.

Positives

• The grant of restricted stock units and options to a key executive like Jean-Luc Lemercier aligns his interests with those of the shareholders.
• The vesting schedule of the options and performance rights encourages long-term performance and retention.

Risks

• The value of the performance rights is contingent on the achievement of specific performance goals, which may not be met.
• The vesting of the options and restricted stock units is subject to continued employment, creating a potential risk if Lemercier were to leave the company.

Future Outlook

The vesting of the restricted stock units and performance rights is contingent upon continued employment and the achievement of performance goals over the next several years.

Industry Context

Executive compensation in the medical device industry often includes stock options and restricted stock units to align executive interests with shareholder value and incentivize long-term growth.

Comparison to Industry Standards

• Stock option grants and restricted stock units are common components of executive compensation packages in the medical device industry, similar to companies like Medtronic, Abbott, and Boston Scientific.
• The vesting schedules and performance-based criteria are also typical, designed to incentivize long-term value creation.

Stakeholder Impact

• Shareholders: The grants align executive interests with shareholder value.
• Employees: The grants are part of the company's overall compensation program.

Key Dates